- Home
- OSTX vs OTLK Comparison
OSTX vs OTLK Comparison
Compare OSTX & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSTX
- OTLK
- Stock Information
- Founded
- OSTX 2018
- OTLK 2010
- Country
- OSTX United States
- OTLK United States
- Employees
- OSTX N/A
- OTLK N/A
- Industry
- OSTX
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OSTX
- OTLK Health Care
- Exchange
- OSTX NYSE
- OTLK Nasdaq
- Market Cap
- OSTX 45.0M
- OTLK 48.3M
- IPO Year
- OSTX 2024
- OTLK 2016
- Fundamental
- Price
- OSTX $1.56
- OTLK $1.77
- Analyst Decision
- OSTX Strong Buy
- OTLK Strong Buy
- Analyst Count
- OSTX 3
- OTLK 5
- Target Price
- OSTX $18.00
- OTLK $10.20
- AVG Volume (30 Days)
- OSTX 340.5K
- OTLK 689.4K
- Earning Date
- OSTX 05-16-2025
- OTLK 05-15-2025
- Dividend Yield
- OSTX N/A
- OTLK N/A
- EPS Growth
- OSTX N/A
- OTLK N/A
- EPS
- OSTX N/A
- OTLK 0.83
- Revenue
- OSTX N/A
- OTLK N/A
- Revenue This Year
- OSTX N/A
- OTLK N/A
- Revenue Next Year
- OSTX N/A
- OTLK $288.46
- P/E Ratio
- OSTX N/A
- OTLK $2.12
- Revenue Growth
- OSTX N/A
- OTLK N/A
- 52 Week Low
- OSTX $1.12
- OTLK $0.87
- 52 Week High
- OSTX $7.00
- OTLK $9.25
- Technical
- Relative Strength Index (RSI)
- OSTX N/A
- OTLK 57.64
- Support Level
- OSTX N/A
- OTLK $1.55
- Resistance Level
- OSTX N/A
- OTLK $1.90
- Average True Range (ATR)
- OSTX 0.00
- OTLK 0.18
- MACD
- OSTX 0.00
- OTLK 0.01
- Stochastic Oscillator
- OSTX 0.00
- OTLK 53.10
About OSTX OS THERAPIES INCORPORATED
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the need for new treatments in cancers of the bone in children and young adults.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.